［1］Gates O，Warren S，Warvi WN.Tumors of sweat glands［J］.Am J Pathol，1943，19(4)：591-631.
［2］Stout AP，Cooley SG.Carcinoma of sweat glands［J］.Cancer，1951，4(3)：521-536.
［3］Nizawa T，Oshitari T，Kimoto R，et al.Early-stage mucinous sweat gland adenocarcinoma of eyelid［J］.Clin Ophthalmol，2011，5：687-689.
［4］Pragya A Nair，Kirti M Rathod，Arvind H Chaudhary，et al.Sweat gland adenocarcinoma of scalp［J］.Int J Trichology，2013，5(4)：208-210.
［5］Berg JW，McDivitt RW.Pathology of sweat gland carcinoma［J］.Pathol Ann，1968，3：123-144.
［6］Gauerke S，Driscoll JJ.Hidradenocarcinomas：a brief review and future directions［J］.Arch Pathol Lab Med，2010，134(5)：781-785.
［7］Toulemonde A，Croue A，Rodien P，et al.Malignant nodular hidradenoma and multiple nodular hidradenomas in a hypogonadic patient［J］.Ann Dermatol Venereol，2006，133(12)：1005-1008.
［8］Singh G，Kumar H，Sridevi NS，et al.Malignant clear cell hidradenoma of the upper eyelid［J］.Electronic Physician，2012，4(2)：490-492.
［9］Falkenstern-Ge RF，Bode-Erdmann S，Ott G，et al.Late lung metastasis of a primary eccrine sweat gland carcinoma 10 years after initial surgical treatment：the first clinical documentation
［J］.Case Rep Oncol Med，2013，2013：167585.
［10］Abhishek Soni，Nupur Bansal，Vivek Kaushal，et al.Current management approach to hidradenocarcinoma：a comprehensive review of the literature［J］.Ecancermedical Science，2015，9：517.
［11］Wang XX，Wang HY，Zheng JN，et al.Primary cutaneous sweat gland carcinoma［J］.J Cancer Res Ther，2014，10(2)：390-392.
［12］Yavel R，Hinshaw M，Rao V，et al.Hidradenomas and a hidradenocarcinoma of the scalp managed using Mohs micrographic surgery and a multidisciplinary approach：case reports and review of
the literature［J］.Dermatol Surg，2009，35(2)：273-281.
［13］Amel T，Olfa G，Faten H，et al.Metastatic hidradenocarcinoma：Surgery and chemotherapy［J］.N Am J Med Sci，2009，1(7)：372-374.
［14］Hollowell KL，Agle SC，Zervos EE，et al.Cutaneous apocrine adenocarcinoma：defining epidemiology，outcomes，and optimal therapy for a rare neoplasm［J］.J Surg Oncol，2012，105(4)：415-
419.
［15］Liapakis IE，Korkolis DP，Koutsoumbi A，et al.Malignant hidrade-noma：a report of two cases and review of the literature［J］.An-ticancer Res，2006，26(3B)：2217-2220.
［16］Lalya I，Hadadi K，Taziel M，et al.Radiotherapy on hidradenocarcinoma［J］.，2011，3(1)：43-45.
［17］Sbai A，Ouabdelmoumene A，Naciri F，et al.Hidradenocarcinoma of the scalp：report of a case［J］.，2014，17：102.
［18］Tolkachjov SN，Hocker TL，Hochwalt PC，et al.Mohs micrographic surgery for the treatment of hidradenocarcinoma：the Mayo Clinic experience from 1993 to 2013［J］.Dermatol Surg，2015，41
(2)：226-231.
［19］Ko CJ，Cochran AJ，Eng W，et al.Hidradenocarcinoma：a histological and immunohistochemical study［J］.J Cutan Pathol，2006，33(11)：726-730.
［20］Belin E，Ezzedine K，Stanislas S，et al.Factors in the surgical management of primary eccrine porocarcinoma：prognostic histological factors can guide the surgical procedure［J］.Br J
Dermatol，2011，165(5)：985-989.
［21］Guillot B.From unusual cutaneous malignancies：cutaneous adnexal tumors［A］.Belkacemi Y，Mirimanoff R，Ozsahin M，et al.Management of rare adult tumors［C］.Paris：Springer-Verlag
France，2009：471-477.
［22］Shiohara J，Koga H，Uhara H，et al.Eccrine porocarcinoma：Clinical and pathological studies of 12 cases［J］.J Dermatol，2007，34(8)：516-522.
［23］Harari PM，Shimm DS，Bangert JL，et al.The role of radiotherapy in the treatment of malignant sweat gland neoplasms［J］.Cancer，1999，65(8)：1737-1740.
［24］Kyrgias G，Kostopoulou E，Zafiriou E et al.Hidradenocarcinoma of the temporal area successfully treated with concomitant electrochemotherapy and radiotherapy［J］.Head Neck Oncol，2013，
5(2)：14.
［25］Vucinic I，Stojadinovic T，Mikez ZB，et al.Apocrine carcinoma of the scalp with aggressive clinical course-a case report and review of the literature［J］.Coll Antropol，2012，36 (2)：
209-212.
［26］Gutermuth J，Audring H，Voit C，et al.Antitumor activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma［J］.J Eur Acad Dermatol Venereol，2004，18(4)：
477-479.
［27］Lerner A，Beckford A，Ugent S，et al.Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment［J］.Arch Dermatol，2011，147(8)：998-999.
［28］Nash JW，Barrett TL，Kies M，et al.Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridation：potential treatment implications
［J］.J Cutan Pathol，2007，34(1)：49-54.
［29］Goldstein R，Stefanato CM，Warbey V，et al.Advanced vulvar apocrine carcinoma expressing estrogen receptors that responds to tamoxifen therapy［J］.Future Oncol，2012，8(9)：1199-1203.
［30］Schrder U，Dries V，Klussmann JP，et al.Successful adjuvant tamoxifen therapy for estrogen receptor-positive metastasizing sweat gland adenocarcinoma：need for a clinical trial
［J］.Ann Otol Rhinol Laryngol，2004，113(3Pt1)：242-244.
［31］Le LP，Dias-Santagata D，Pawlak AC，et al.Apocrine-eccrine carcinomas：molecular and immunohistochemical analyses［J］.PLoS One，2012，7(10)：e47290.
［32］Leilei Zhang，Shengfang Ge，Xianqun Fan.A brief review of different types of sweat-gland carcinomas in the eyelid and orbit［J］.Onco Targets Ther，2013，6：331-340.